Why Attend?
- Recreational marijuana use is legal in 10 US states, while medicinal marijuana is legal in 33
- CBD oils and CBD-containing products are appearing in specialty shops, pharmacies, and medical marijuana dispensaries.
- Recent polls reveal that 55 million Americans currently use marijuana and one in every seven adults uses CBD products.
- There is an increased possibility that members of the general public will be consuming cannabis or CBD along with prescription or over-the-counter medications.
- As evidenced by the May 31, 2019 FDA public hearing, many other questions exist surrounding CBD safety in regard to consumption levels, consuming multiple products simultaneously, pregnancy and child exposure to CBD products, and prolonged usage of CBD.
This program is presented through a grant from Greenwich Bioscience.
Who should attend:
- Healthcare Professionals who have patients using medical or recreational marijuana, especially who practice in states with legalized or decriminalized recreational marijuana
- Healthcare Professionals who have added or are considering adding CBD products to their practice
- Healthcare Professionals with patients using OTC products containing CBD purchased elsewhere
- Healthcare Professionals who work in dispensaries
PROGRAM
Welcome & Introductions
Susan Bartlemay, RPh, FACA, FAPhA, Executive Vice-President, American College of Apothecaries
Beyond the Buzz: Legal and Regulatory Issues Relating to CBD
Alice Mead, JD, LLM, Vice President of US Public Policy, Greenwich Biosciences (bio) ↓ Download Presentation
CBD: Clinical Data and Quality Considerations
Kathryn Nichol, PhD Senior Director, Medical Affairs, Greenwich Biosciences (bio)↓ Download Presentation
Cannabis and Your Patient: The Good, The Bad, and The Ugly
Thomas C. Kupiec, PhD, President and CEO, ARL Bio Pharma (bio)↓ Download Presentation
Making Sense of the Cannabis Chaos
Daniel A. Hussar, PhD, Dean Emeritus and Remington Professor Emeritus of the Philadelphia College of Pharmacy, University of the Sciences (bio)
↓ Download Presentation
Organizing a CBD Education and Awareness Campaign
Fred Mayer, RPh, MPH, FACA, Chairman, PPHI (bio)↓ Download Presentation
Dr. Thomas Kupiec is CEO of ARL Bio Pharma and DNA Solutions. Dr. Kupiec received his Ph.D. in Pharmaceutical Sciences from the University of Oklahoma Health Sciences Center College of Pharmacy.
Ms. Mead received her Juris Doctor degree from University of Santa Clara School of Law and her Master of Law degree from Yale. She served for twelve years as an in-house counsel to the California Medical Association (CMA), one of the largest state medical associations in the country. Prior to that time, Ms. Mead was a litigation associate at a global law firm and an Assistant Professor of Law at Arizona State University College of Law, where she taught courses in constitutional law. Since 1999 she has served as Vice President, U.S. Public Policy and Public Affairs, for GW Pharmaceuticals (and its U.S. subsidiary, Greenwich Biosciences), one of the first companies in the world to develop cannabis-derived medications as prescription products in adherence to modern scientific and regulatory standards for pharmaceutical products. She focuses on domestic and international drug control laws and policy issues.